ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: View All • a b c d e f g h i j k l m n o p q r s t u [v] w x y z

Abstract Number: 2613

Vaccination Is Associated with Lower Risk of Parenchymal Lung Disease in Patients with Rheumatoid Arthritis After COVID-19: Results from a Prospective Study
Abstract Number: 0977

Vaccine Effectiveness and Safety of Recombinant Zoster Vaccine (RZV) in Rheumatoid Arthritis (RA) Patient Populations Aged 50 Years and Older
Abstract Number: 0025

Vagus Nerve Stimulation: A Promising Approach to Alleviate Pain and Systemic Inflammation in Slow and Rapid Models of Osteoarthritis
Abstract Number: 1874

Validation Analysis of the Expanded Risk Score for Rheumatoid Arthritis in a Multicentre Italian Cohort
Abstract Number: 2395

Validation Cohort of a Tool to Predict Proliferative Histological Class in Lupus Nephritis Based on Clinical and Laboratory Data – LUCAS Study (Lupus Nephritis Class Assessment System)
Abstract Number: 1588

Validation of a Lung Ultrasound Interpretation Criteria for Interstitial Lung Disease Screening in Systemic Sclerosis and Inflammatory Myopathy
Abstract Number: 1509

Validation of a Score for the Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus: Data from a Latin American Lupus Cohort
Abstract Number: 0821

Validation of ASAS Preliminary Data-Driven MRI Lesion Cut-offs for a Positive MRI of the Sacroiliac Joints in Patients with Axial Spondyloarthritis and Subgroups with Psoriasis, Iritis, and Colitis
Abstract Number: 1970

Validation of Handheld Ultrasound Devices for Point of Care Use in Rheumatology: Interim Analysis for Enthesitis
Abstract Number: 0398

Validation of Patient-Reported Outcomes Measurement Information System® (PROMIS®) Pediatric Measures for Children with Chronic Nonbacterial Osteomyelitis Using the CHOIR Data
Abstract Number: 2412

Validation of Proposals for Definitions of Moderate and Severe Disease Activity in Systemic Lupus Erythematosus, Based on Data Gathered from the RELESSER-PROS Register Database
Abstract Number: 0117

Validation of the 2023 American College of Rheumatology/European League Against Rheumatism Antiphospholipid Syndrome Classification Criteria in the Pediatric Population
Abstract Number: 2146

Validation of the Simple Calculated Osteoporosis Risk Estimation and Osteoporosis Self-assessment Tool Among People Aging with HIV in Peru
Abstract Number: 2223

Validation Study in Early Rheumatoid Arthritis Patients of the Spanish Society of Rheumatology (SER)/Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) Screening Criteria for Interstitial Lung Disease
Abstract Number: 0326

Validity and Responsiveness of Core Set Measures in Idiopathic Inflammatory Myositis Based on 36-item Short Form Health Survey (SF-36)
Abstract Number: 0661

Validity, Reliability and Responsiveness of Lupus Impact Tracker and LupusPRO: AURORA Trial
Abstract Number: 0593

Value of the Routine Assessment of Patient Index Data 3 in Assessing Disease Severity and Treatment Effect in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast
Abstract Number: 1674

Variability in Pain and Depression Measures Between Adolescent Patients with Rheumatic Disease and Caregivers
Abstract Number: 0386

Variability of Data Completeness and Consensus Treatment Plan Adherence for Polyarticular Juvenile Idiopathic Arthritis Patients Within the Childhood Arthritis and Rheumatology Research Alliance Registry
Abstract Number: 1535

Variations in Tacrolimus Whole Blood Concentrations During Pregnancy and Its Implications for Therapeutic Drug Monitoring: A Systematic Review and Meta-analysis
Abstract Number: 0120

Vascular Liver Disorders in Patients with Antiphospholipid Syndrome: A Retrospective National Multicentre Study
Abstract Number: 2651

Vasculitis Associated with VEXAS Syndrome
Abstract Number: 1559

Vectorcardiography for Identification of Systemic Sclerosis Patients at Risk for Pulmonary Hypertension
Abstract Number: 1901

Venous Thromboembolism Risk Is Consistently Increased in People with Rheumatoid Arthritis Across Different Ages, Sexes and Obesity Status: United Kingdom Population Based Study
Abstract Number: 1049

Very Low Uptake of Biosimilar Adalimumab in the First 9 Months of Availability in Rheumatology
Abstract Number: 1943

Virtual Rheumatology in the Real World: Use of Telemonitoring to Optimize the Management of Patients with Rheumatoid Arthritis
Abstract Number: 0992

Visceral Adipose Tissue Measured by DXA Predicts Metabolic Syndrome in Low-Income Community-Dwelling Elderly: Insights from the São Paulo Ageing & Health (SPAH) Study
Abstract Number: 2549

VISTA Deficiency Alters the Skin Immune Cell Composition and Confers Skin Sensitivity to UV Light
Abstract Number: 2098

Vitamin D Deficiency Is Associated with Progression of Radiographic Hand Osteoarthritis in a 6-year Follow-up of the Dong-gu Study
Abstract Number: 1616

Vitamin D Supplementation in the Prevention of Severe Adverse Effects Caused ByGlucocorticoids: Study from the ARTESER Registry of Giant Cell Arteritis
Abstract Number: 2428

Vitamin-D Effect on SLE- Scoping Review
Abstract Number: 1884

VIVA QI: Vaccination In Vasculitis: Applying a Quality Improvement Approach
Abstract Number: 2581

Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study

Jump to: View All • a b c d e f g h i j k l m n o p q r s t u [v] w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].